CRE RESPOND is a multi-institutional collaborative dedicated to reducing the burden of antimicrobial resistance through optimal personalised antimicrobial dosing. The Centre was formerly supported by a $2.5 million National Health and Medical Research Council (NHMRC) Centre of Research Excellence grant from 2021 to 2026, bringing together researchers, clinicians and industry partners to advance precision antimicrobial therapy.

Infection causes unacceptably high morbidity and mortality worldwide. It is common for Australian clinicians to be confronted by patients who are infected by pathogens that are resistant to all available antimicrobials. 

CRE RESPOND addresses antimicrobial resistance and poor patient outcomes through evidence-based personalised antimicrobial drug dosing. By generating new knowledge and translating research into practice, CRE RESPOND supports improvements in patient care, health systems, and antimicrobial stewardship.

The Centre's work has informed policy, clinical guidelines and practice, while fostering national and international collaborations and developing the next generation of researchers and clinical leaders in the field.

CRE RESPOND aims to:
  • Generate new knowledge that leads to improved health outcomes.
  • Promote the translation of research findings into health policy and clinical practice.
  • Develop the health and medical research workforce through training, mentorship and leadership opportunities.
  • Facilitate multidisciplinary and multi-institutional collaboration.
  • Advance the implementation of personalised antimicrobial dosing strategies to combat antimicrobial resistance.